Form 8-K BRISTOL MYERS SQUIBB CO For: Feb 04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Bristol-Myers Squibb Co. (BMY) PT Raised to $74 at BMO Capital
February 7, 2022 7:21 AM ESTBMO Capital analyst Evan David Seigerman raised the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $74.00 (from $72.00) while maintaining an Outperform rating.
The analyst commented, "Concerns around Revlimids erosion still overshadow the growth from the new product portfolio, but the... More
